
Ishak Laboratory
Charles A. Ishak, Ph.D.
Principal Investigator
- Departments, Labs and Institutes
- Labs
- Ishak Laboratory
Areas of Research
- Epigenetics
- Chromatin
- Premalignancy
- p53
- Ovarian Cancer
- Molecular Carcinogenesis
Research in the Ishak laboratory explores the contributions of repetitive DNA elements in cancer initiation, progression and therapeutic response with the goal of both improving cancer immunotherapies and developing novel approaches for cancer interception and immunoprevention.
Repetitive DNA sequences comprise nearly half of the human genome. Originally considered “junk DNA,” certain classes of repetitive DNA elements have more recently been associated with cancer development and as effectors of epigenetic therapies that augment cancer immunotherapy (Cancer Discovery, 2021). However, how repetitive DNA elements function in cancer initiation and cancer immunotherapy response is not only controversial but also paradoxical (Annual Review of Cancer Biology, 2020).
Our Research Goal
We aim to define the roles of repetitive DNA elements in cancer initiation, development and therapeutic response.
Join Our Lab
The Ishak lab is recruiting highly motivated individuals interested in cancer epigenetics and molecular biology.
Charles A. Ishak, Ph.D.
Principal Investigator
B.Sc. Molecular Biology, University of Toronto, Toronto, Canada
Ph.D. Biochemistry, Western University, London, Canada
caishak@mdanderson.org
Research Interests: Repetitive DNA elements as cancer initiators and immune response modulators, viral mimicry, ovarian and p53-mutated cancers